Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma

To explore the efficacy of Tislelizumab combined with chemotherapy in the treatment of locally unresectable esophageal squamous cell carcinoma (ESCC)

Trial Details

NCT ID
NCT05515315
Phase
PHASE2
Sponsor
Fuzhou General Hospital
Status
RECRUITING
Cancer Type
Esophageal Cancer
Interventions
  • Tislelizumab
  • Albumin paclitaxel
  • Nedaplatin
  • radiotherapy
Locations (sample)
  • Fuzhou, Fujian, China|26.06139,119.30611

Key Eligibility Criteria

  • Histologically confirmed localized ESCC that is suitable for cCRT, including: stage II-IVA (AJCC version 8) inoperable ESCC (medically unfit for su…
  • Aged 18-70, both sexes;
  • ECOG score 0-1
  • The presence of measurable and/or nonmeasurable lesions that met the definition of RECIST1.1;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Esophageal Cancer Trials on Trialify →